Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Analyst Ratings
Strong Buy
11 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SMMT Stock 12 Month Forecast
Average Price Target
$36.25
▲(41.16% Upside)
| Highest Price Target$44.00 | Average Price Target$36.25 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Clear Street
$30→$33
Buy
28.50%
Upside
Reiterated
08/13/25
Truist Financial
―
Buy
―
Reiterated
08/13/25
Evercore ISI
$30→$34
Buy
32.40%
Upside
Reiterated
08/12/25
Citi
$35
Buy
36.29%
Upside
Assigned
08/12/25
TD Cowen
―
Buy
―
Reiterated
08/12/25
H.C. Wainwright
$44
Buy
71.34%
Upside
Reiterated
08/12/25
Ivonescimab's Promising Potential to Outperform KEYTRUDA: A Strong Buy RecommendationValuation and Risks. Using an 8% discount rate and 4% terminal growth rate, our DCF-based analysis results in an estimated EV of ~$37B, resulting in a price objective of $44 per share. We believe this discount rate is appropriate given the clinical data for ivonescimab as well as the extensive validation of PD-1 as a target via Keytruda's 40 prior regulatory approvals. Similarly, we believe that our 4% terminal growth rate factors in the myriad shots on goal from the large array of potential future indications. We do not include any of these non-core indications in our current valuation.
Wells Fargo
$30
Buy
16.82%
Upside
Assigned
08/11/25
Cantor Fitzgerald
―
Buy
―
Reiterated
07/28/25
Leerink Partners
―
Sell
―
Reiterated
07/03/25
We believe SMMT could trade up should the upfront exceed $7.7Bn (more than double what BMY paid), and the partners commit to a development portfolio that enables street expectations for ivo to reach a quarter of Keytruda sales. However, we question whether a pharmacos is a buyer of ivo at this price: 1 Though SMMT is ahead of BNTX in Ph3 global trials, BNTX has a portfolio of assets the company is already combining with BNT327. 2 There are numerous VEGF-A/PD-(L)1s in development in and outside of China, which we presume will be cheaper to license in royalty deals, which also give the licensor more control over development. For example, we expect companies may prefer to move forward on their own rather than inherit SMMT's higher-risk Ph3 HARMONi-3 trial in 1L squamous and nonsquamous non-small cell lung cancer.
UBS
$30
Buy
16.82%
Upside
Initiated
06/30/25
Citizens JMP
$40
Buy
55.76%
Upside
Reiterated
06/02/25
Jefferies
$44
Buy
71.34%
Upside
Reiterated
05/31/25
Stifel Nicolaus
$40
Buy
55.76%
Upside
Reiterated
03/11/25
Goldman Sachs
$42
Buy
63.55%
Upside
Initiated
02/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Clear Street
$30→$33
Buy
28.50%
Upside
Reiterated
08/13/25
Truist Financial
―
Buy
―
Reiterated
08/13/25
Evercore ISI
$30→$34
Buy
32.40%
Upside
Reiterated
08/12/25
Citi
$35
Buy
36.29%
Upside
Assigned
08/12/25
TD Cowen
―
Buy
―
Reiterated
08/12/25
H.C. Wainwright
$44
Buy
71.34%
Upside
Reiterated
08/12/25
Ivonescimab's Promising Potential to Outperform KEYTRUDA: A Strong Buy RecommendationValuation and Risks. Using an 8% discount rate and 4% terminal growth rate, our DCF-based analysis results in an estimated EV of ~$37B, resulting in a price objective of $44 per share. We believe this discount rate is appropriate given the clinical data for ivonescimab as well as the extensive validation of PD-1 as a target via Keytruda's 40 prior regulatory approvals. Similarly, we believe that our 4% terminal growth rate factors in the myriad shots on goal from the large array of potential future indications. We do not include any of these non-core indications in our current valuation.
Wells Fargo
$30
Buy
16.82%
Upside
Assigned
08/11/25
Cantor Fitzgerald
―
Buy
―
Reiterated
07/28/25
Leerink Partners
―
Sell
―
Reiterated
07/03/25
We believe SMMT could trade up should the upfront exceed $7.7Bn (more than double what BMY paid), and the partners commit to a development portfolio that enables street expectations for ivo to reach a quarter of Keytruda sales. However, we question whether a pharmacos is a buyer of ivo at this price: 1 Though SMMT is ahead of BNTX in Ph3 global trials, BNTX has a portfolio of assets the company is already combining with BNT327. 2 There are numerous VEGF-A/PD-(L)1s in development in and outside of China, which we presume will be cheaper to license in royalty deals, which also give the licensor more control over development. For example, we expect companies may prefer to move forward on their own rather than inherit SMMT's higher-risk Ph3 HARMONi-3 trial in 1L squamous and nonsquamous non-small cell lung cancer.
UBS
$30
Buy
16.82%
Upside
Initiated
06/30/25
Citizens JMP
$40
Buy
55.76%
Upside
Reiterated
06/02/25
Jefferies
$44
Buy
71.34%
Upside
Reiterated
05/31/25
Stifel Nicolaus
$40
Buy
55.76%
Upside
Reiterated
03/11/25
Goldman Sachs
$42
Buy
63.55%
Upside
Initiated
02/28/25
Best Analysts Covering Summit Therapeutics
1 Month
xxx
Success Rate
6/7 ratings generated profit
Average Return
+16.71%
assigned a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +16.71% per trade.
3 Months
xxx
Success Rate
7/7 ratings generated profit
Average Return
+46.20%
assigned a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.20% per trade.
1 Year
Success Rate
7/7 ratings generated profit
Average Return
+253.83%
reiterated a buy rating 5 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +253.83% per trade.
2 Years
xxx
Success Rate
7/7 ratings generated profit
Average Return
+317.09%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +317.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SMMT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
13
11
12
11
9
Buy
14
19
23
14
12
Hold
12
10
6
1
0
Sell
0
0
2
3
3
Strong Sell
0
0
0
0
0
total
39
40
43
29
24
Each month's total comprises the sum of three months' worth of ratings.
SMMT Financial Forecast
SMMT Stock Forecast FAQ
What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 36.25.
What is SMMT’s upside potential, based on the analysts’ average price target?
Summit Therapeutics has 41.16% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SMMT a Buy, Sell or Hold?
Summit Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 1 sell ratings.
What is Summit Therapeutics’s price target?
The average price target for Summit Therapeutics is 36.25. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $44.00 ,the lowest forecast is $30.00. The average price target represents 41.16% Increase from the current price of $25.68.
The highest analyst price target is $44.00 ,the lowest forecast is $30.00. The average price target represents 41.16% Increase from the current price of $25.68.
What do analysts say about Summit Therapeutics?
Summit Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of SMMT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.